Report cover image

Specific COX-2 Inhibitors Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 137 Pages
SKU # APRC20260612

Description

Summary

According to APO Research, the global Specific COX-2 Inhibitors market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Specific COX-2 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Specific COX-2 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Specific COX-2 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Specific COX-2 Inhibitors include Actavis, Eskayef Pharmaceuticals, Mylan Pharmaceutical, Neopharmed Gentili, Organon Pharma, Pfizer, Teva, Zentiva and Zydus, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Specific COX-2 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Specific COX-2 Inhibitors.

The report will help the Specific COX-2 Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Specific COX-2 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Specific COX-2 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Specific COX-2 Inhibitors Segment by Company

Actavis
Eskayef Pharmaceuticals
Mylan Pharmaceutical
Neopharmed Gentili
Organon Pharma
Pfizer
Teva
Zentiva
Zydus
Beijing Yabao Biological Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Jiangsu Chiatai Qingjiang Pharmaceutical
Qilu Pharmaceutical
Qingdao Baheal Medical
Shanxi Tongda Pharmaceutical
Sichuan Kelun Pharmaceutical
Specific COX-2 Inhibitors Segment by Type

Etoricoxib
Celecoxib
Imrecoxib
Other
Specific COX-2 Inhibitors Segment by Application

Osteoarthritis and Rheumatoid Arthritis
Relieve Acute Pain
Dysmenorrhea
Other
Specific COX-2 Inhibitors Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Specific COX-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Specific COX-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Specific COX-2 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Specific COX-2 Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Specific COX-2 Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Specific COX-2 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

137 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Specific COX-2 Inhibitors Market Size (2020-2031)
2.2.2 Global Specific COX-2 Inhibitors Sales (2020-2031)
2.2.3 Global Specific COX-2 Inhibitors Market Average Price (2020-2031)
2.3 Specific COX-2 Inhibitors by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Etoricoxib
2.3.3 Celecoxib
2.3.4 Imrecoxib
2.3.5 Other
2.4 Specific COX-2 Inhibitors by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Osteoarthritis and Rheumatoid Arthritis
2.4.3 Relieve Acute Pain
2.4.4 Dysmenorrhea
2.4.5 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Specific COX-2 Inhibitors Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Specific COX-2 Inhibitors Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Specific COX-2 Inhibitors Revenue of Manufacturers (2020-2025)
3.4 Global Specific COX-2 Inhibitors Average Price by Manufacturers (2020-2025)
3.5 Global Specific COX-2 Inhibitors Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Specific COX-2 Inhibitors, Product Type & Application
3.8 Global Manufacturers of Specific COX-2 Inhibitors, Established Date
3.9 Global Specific COX-2 Inhibitors Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Actavis
4.1.1 Actavis Company Information
4.1.2 Actavis Business Overview
4.1.3 Actavis Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Actavis Specific COX-2 Inhibitors Product Portfolio
4.1.5 Actavis Recent Developments
4.2 Eskayef Pharmaceuticals
4.2.1 Eskayef Pharmaceuticals Company Information
4.2.2 Eskayef Pharmaceuticals Business Overview
4.2.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
4.2.5 Eskayef Pharmaceuticals Recent Developments
4.3 Mylan Pharmaceutical
4.3.1 Mylan Pharmaceutical Company Information
4.3.2 Mylan Pharmaceutical Business Overview
4.3.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
4.3.5 Mylan Pharmaceutical Recent Developments
4.4 Neopharmed Gentili
4.4.1 Neopharmed Gentili Company Information
4.4.2 Neopharmed Gentili Business Overview
4.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
4.4.5 Neopharmed Gentili Recent Developments
4.5 Organon Pharma
4.5.1 Organon Pharma Company Information
4.5.2 Organon Pharma Business Overview
4.5.3 Organon Pharma Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
4.5.5 Organon Pharma Recent Developments
4.6 Pfizer
4.6.1 Pfizer Company Information
4.6.2 Pfizer Business Overview
4.6.3 Pfizer Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
4.6.5 Pfizer Recent Developments
4.7 Teva
4.7.1 Teva Company Information
4.7.2 Teva Business Overview
4.7.3 Teva Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
4.7.5 Teva Recent Developments
4.8 Zentiva
4.8.1 Zentiva Company Information
4.8.2 Zentiva Business Overview
4.8.3 Zentiva Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
4.8.5 Zentiva Recent Developments
4.9 Zydus
4.9.1 Zydus Company Information
4.9.2 Zydus Business Overview
4.9.3 Zydus Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Zydus Specific COX-2 Inhibitors Product Portfolio
4.9.5 Zydus Recent Developments
4.10 Beijing Yabao Biological Pharmaceutical
4.10.1 Beijing Yabao Biological Pharmaceutical Company Information
4.10.2 Beijing Yabao Biological Pharmaceutical Business Overview
4.10.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
4.10.5 Beijing Yabao Biological Pharmaceutical Recent Developments
4.11 Jiangsu Hengrui Pharmaceuticals
4.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
4.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
4.11.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
4.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
4.12 Jiangsu Chiatai Qingjiang Pharmaceutical
4.12.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
4.12.2 Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
4.12.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
4.12.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
4.13 Qilu Pharmaceutical
4.13.1 Qilu Pharmaceutical Company Information
4.13.2 Qilu Pharmaceutical Business Overview
4.13.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
4.13.5 Qilu Pharmaceutical Recent Developments
4.14 Qingdao Baheal Medical
4.14.1 Qingdao Baheal Medical Company Information
4.14.2 Qingdao Baheal Medical Business Overview
4.14.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
4.14.5 Qingdao Baheal Medical Recent Developments
4.15 Shanxi Tongda Pharmaceutical
4.15.1 Shanxi Tongda Pharmaceutical Company Information
4.15.2 Shanxi Tongda Pharmaceutical Business Overview
4.15.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
4.15.5 Shanxi Tongda Pharmaceutical Recent Developments
4.16 Sichuan Kelun Pharmaceutical
4.16.1 Sichuan Kelun Pharmaceutical Company Information
4.16.2 Sichuan Kelun Pharmaceutical Business Overview
4.16.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
4.16.5 Sichuan Kelun Pharmaceutical Recent Developments
5 Global Specific COX-2 Inhibitors Market Scenario by Region
5.1 Global Specific COX-2 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Specific COX-2 Inhibitors Sales by Region: 2020-2031
5.2.1 Global Specific COX-2 Inhibitors Sales by Region: 2020-2025
5.2.2 Global Specific COX-2 Inhibitors Sales by Region: 2026-2031
5.3 Global Specific COX-2 Inhibitors Revenue by Region: 2020-2031
5.3.1 Global Specific COX-2 Inhibitors Revenue by Region: 2020-2025
5.3.2 Global Specific COX-2 Inhibitors Revenue by Region: 2026-2031
5.4 North America Specific COX-2 Inhibitors Market Facts & Figures by Country
5.4.1 North America Specific COX-2 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Specific COX-2 Inhibitors Sales by Country (2020-2031)
5.4.3 North America Specific COX-2 Inhibitors Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Specific COX-2 Inhibitors Market Facts & Figures by Country
5.5.1 Europe Specific COX-2 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Specific COX-2 Inhibitors Sales by Country (2020-2031)
5.5.3 Europe Specific COX-2 Inhibitors Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Specific COX-2 Inhibitors Market Facts & Figures by Country
5.6.1 Asia Pacific Specific COX-2 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Specific COX-2 Inhibitors Sales by Country (2020-2031)
5.6.3 Asia Pacific Specific COX-2 Inhibitors Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Specific COX-2 Inhibitors Market Facts & Figures by Country
5.7.1 South America Specific COX-2 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Specific COX-2 Inhibitors Sales by Country (2020-2031)
5.7.3 South America Specific COX-2 Inhibitors Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.7.7 Colombia
5.8 Middle East and Africa Specific COX-2 Inhibitors Market Facts & Figures by Country
5.8.1 Middle East and Africa Specific COX-2 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2020-2031)
5.8.3 Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Specific COX-2 Inhibitors Sales by Type (2020-2031)
6.1.1 Global Specific COX-2 Inhibitors Sales by Type (2020-2031) & (K Units)
6.1.2 Global Specific COX-2 Inhibitors Sales Market Share by Type (2020-2031)
6.2 Global Specific COX-2 Inhibitors Revenue by Type (2020-2031)
6.2.1 Global Specific COX-2 Inhibitors Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Specific COX-2 Inhibitors Revenue Market Share by Type (2020-2031)
6.3 Global Specific COX-2 Inhibitors Price by Type (2020-2031)
7 Segment by Application
7.1 Global Specific COX-2 Inhibitors Sales by Application (2020-2031)
7.1.1 Global Specific COX-2 Inhibitors Sales by Application (2020-2031) & (K Units)
7.1.2 Global Specific COX-2 Inhibitors Sales Market Share by Application (2020-2031)
7.2 Global Specific COX-2 Inhibitors Revenue by Application (2020-2031)
7.2.1 Global Specific COX-2 Inhibitors Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Specific COX-2 Inhibitors Revenue Market Share by Application (2020-2031)
7.3 Global Specific COX-2 Inhibitors Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Specific COX-2 Inhibitors Value Chain Analysis
8.1.1 Specific COX-2 Inhibitors Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Specific COX-2 Inhibitors Production Mode & Process
8.2 Specific COX-2 Inhibitors Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Specific COX-2 Inhibitors Distributors
8.2.3 Specific COX-2 Inhibitors Customers
9 Global Specific COX-2 Inhibitors Analyzing Market Dynamics
9.1 Specific COX-2 Inhibitors Industry Trends
9.2 Specific COX-2 Inhibitors Industry Drivers
9.3 Specific COX-2 Inhibitors Industry Opportunities and Challenges
9.4 Specific COX-2 Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.